{"id":2734,"date":"2019-08-29T18:50:00","date_gmt":"2019-08-29T18:50:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-profit-in-the-first-six-months-of-2019-increases-by-14-and-reaches-7-65-million-euro\/"},"modified":"2022-07-04T18:53:21","modified_gmt":"2022-07-04T18:53:21","slug":"grindeks-profit-in-the-first-six-months-of-2019-increases-by-14-and-reaches-7-65-million-euro","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-profit-in-the-first-six-months-of-2019-increases-by-14-and-reaches-7-65-million-euro\/","title":{"rendered":"2019. gada pirmaj\u0101 pusgad\u0101 Grindeks pe\u013c\u0146a pieaug par 14% un sasniedz 7,65 milj. eiro"},"content":{"rendered":"\n

\u0160odien, 29. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2019. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, ir sasniegusi 7,65 milj. eiro. Sal\u012bdzinot ar 2018. gada pirmo pusgadu, pe\u013c\u0146a ir palielin\u0101jusies par 0,92 milj. eiro vai par 14%. Koncerna apgroz\u012bjums 2019. gada pirmaj\u0101 pusgad\u0101 bija 69,0 milj. eiro, kas ir par 2,6 milj. eiro vai par 4% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 pusgad\u0101.<\/p>\n\n\n\n

AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eLai visa koncerna l\u012bmen\u012b k\u013c\u016btu par pacientu-orient\u0113tu farm\u0101cijas industrijas p\u0101rst\u0101vi, m\u0113s savas darb\u012bbas centr\u0101 ap\u0146\u0113m\u012bgi izvirz\u0101m pacientu. M\u016bsu ilgtsp\u0113jas biznesa modelis un jaun\u0101 komercpolitika paredz past\u0101v\u012bgu produktu portfe\u013ca pilnveidi, ievie\u0161ot jaunus, kompleksus risin\u0101jumus pacientu vajadz\u012bbu apmierin\u0101\u0161anai. Vienlaikus m\u0113s atsak\u0101mies no produktiem, kuru rentabilit\u0101te un ra\u017eo\u0161anas apjomi ir mazi. T\u0101d\u0113j\u0101di pirmaj\u0101 pusgad\u0101 esam uzlaboju\u0161i koncerna neto pe\u013c\u0146as rentabilit\u0101ti un iev\u0113rojami k\u0101pin\u0101ju\u0161i pe\u013c\u0146as r\u0101d\u012bt\u0101ju, sasniedzot 7,65 milj. eiro pe\u013c\u0146u, kas dod noz\u012bm\u012bgu atsp\u0113rienu uz\u0146\u0113muma att\u012bst\u012bbai. Apgroz\u012bjuma samazin\u0101jums ir neb\u016btisks, un tam paredzams \u012bstermi\u0146a raksturs.\u201d<\/em><\/p>\n\n\n\n

2019. gada pirmaj\u0101 pusgad\u0101 Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 68 pasaules valst\u012bm kopum\u0101 par 64,2 milj. eiro, kas ir par 1,5 milj. eiro vai par 2% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 pusgad\u0101.
Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2019. gada pirmaj\u0101 pusgad\u0101 bija 63,0 milj. eiro un ir samazin\u0101jies, sal\u012bdzinot ar 2018. gada pirmo pusgadu, par 2,6 milj. eiro. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2019. gada pirmaj\u0101 pusgad\u0101 veidoja 38,4 milj. eiro, kas ir par 4,7 milj. eiro vai par 11% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 pusgad\u0101. Sal\u012bdzinot ar 2018. gada pirmo pusgadu, 2019. gada pirmaj\u0101 pusgad\u0101 noz\u012bm\u012bgs p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Gruzij\u0101 par 27%, Baltkrievij\u0101 par 25%, Kirgizst\u0101n\u0101 par 24%, Arm\u0113nij\u0101 par 18% un Moldov\u0101 par 16%.<\/p>\n\n\n\n

Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2019. gada pirmaj\u0101 pusgad\u0101 sasniedza 23,3 milj. eiro, kas ir par 2,1 milj. eiro vai 10% vair\u0101k nek\u0101 2018. gada pirmaj\u0101 pusgad\u0101.
2019. gada pirmaj\u0101 pusgad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 5,1 milj. eiro, kas ir par 0,81 milj. eiro vai 19% vair\u0101k nek\u0101 2018. gada pirmaj\u0101 pusgad\u0101. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tika veikts uz ES valst\u012bm, Jap\u0101nu, Austr\u0101liju un Kan\u0101du. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2019. gada pirmaj\u0101 pusgad\u0101 bija deksmedetomid\u012bns, detomid\u012bns un oksitoc\u012bns.<\/p>\n","protected":false},"excerpt":{"rendered":"

\u0160odien, 29. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2019. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes…<\/p>\n","protected":false},"author":3,"featured_media":2731,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2734","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2734"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2734\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2731"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}